The Medicines — Medicines — Merger or Acquisition (December 2012)
35 slides from The Medicines's merger presentation, Dec 17, 2012
Slide 1: Building the Global Leader in Acute and Intensive Care Medicine
THE MEDICINES COMPANY BUILDING THE GLOBAL LEADER IN ACUTE AND INTENSIVE CARE MEDICINE Update for Investors December 17th – 20th 2012
Slide 2: Notices: Forward looking statements
Notices Forward looking statements Statements contained in these slides about The Medicines Company (the “Company”), the Company's products and product candidates, the timing of clinical trial results, regulatory submissions, product or indication launches, the Company’s future financial and operati
Slide 3: Contents
Contents Last week MDCO announced two significant transactions for growth PART I SUMMARY PART II BACKGROUND | RATIONALE | PROCESS Our focus on acute | intensive hospital medicine remains constant Building an acute | intensive care portfolio Progress since 2010 8 10 12 PART III STRATEGIC FIT Criteria
Slide 4: Summary
SUMMARY pages MOCO: ulding the Global Leader in Ate and intensive Care Meine | Investor Update December 17-8 2012
Slide 5: Summary: What did we acquire?
Summary What did we acquire...? Two potentially segment-leading assets in the acute | intensive care surgical market. Anticipated closing 1Q13. Subject to regulatory review. Recombinant human thrombin & applicators Topical aid to hemostasis in surgery Marketed in the United States and Canada Estimat
Slide 6: Summary: What did we pay?
Summary What did we pay...? Total of $300M cash upfront. Both deals include downstream payments if products are successful Upfront collaboration payment $105M Upfront option fee $10M Tiered royalties for 2 years Double digit % Purchase price based on 2013-14 sales nd Total purchase price estimate 3.
Slide 7: Summary: Growth and financial consequences of the deals
Summary What growth and financial consequences do we foresee from these deals...? Accretion | dilution Recothrom® deal is expected to be accretive to earnings in 2013 Incline Therapeutics deal is expected to be modestly dilutive for 2013-14 Combined the deals are neutral to slightly negative on a 20
Slide 8: Background | Rationale | Process
BACKGROUND | RATIONALE | PROCESS
Slide 9: Our focus on acute | intensive hospital care remains constant
Implementation of strategy Our focus on acute | intensive hospital care remains constant Strategy articulated since 2006 Expected to create significant value for shareholders Purpose To save lives, alleviate suffering and improve the economic efficiency of the ~2,500 leading acute | intensive care h
Slide 10: Scope of business development activities since 2006
Implementation of strategy Our focus on acute | intensive hospital care remains constant Scope of business development activities since 2006: more than 500 assets reviewed PHARM Pharmacy Services ECARD ECG diagnostics BBANK Blood Bank CTSCA Computer. Tomograph Imaging MRI Magnetic Resonance Imaging
Slide 11: Building an acute | intensive care portfolio
Implementation of strategy Building an acute | intensive care portfolio Twenty assets acquired or invested-in Name Route Class Patients Stage Launch (e = est.) 2012 sales (estimated) Peak sales (estimated) Angio(ma)x® (bivlairudin) Injectable Thrombin inhibitor anticoagulant Patients undergoing perc
Slide 12: Assets can serve similar audiences
Implementation of strategy Building an acute | intensive care portfolio Assets can serve similar audiences – interventional cardiology, surgery, emergency room, perioperative care Name Route Class Patients Principal audience Angio(ma)x® (bivlairudin) Injectable Thrombin inhibitor anticoagulant Patie
Slide 13: Progress since 2010
Implementation of strategy Progress since 2010 2010 3Q - Angiomax® US exclusivity period clarified Reaffirmed growth strategy 2012 3Q - raised $275M in convertible debt offering. End 3Q 2012, $535M Before these deals -- we expected to end the year 2012 at $560-$565M cash in hand 2012 2Q - reinforced
Slide 14: Strategic Fit
STRATEGIC FIT page 4 [MOCO: ulding the Global Leader in Acute and intensive Care Medicine | Investor Update December 17-189 2012
Slide 15: Criteria for innovation
Strategic fit Criteria for innovation All of our criteria for a fit with our growing business were met for both products Criteria Recothrom® Ionsys® Overlapping institutions from our global target list 100% with Cleviprex® 100% with Cleviprex® Worldwide rights Yes Yes Effectiveness data available Ye
Slide 16: Recothrom
Strategic fit Recothrom® Recothrom is a topical hemostat used as an aid to hemostasis to help control oozing blood and mild bleeding during surgical procedures. It is a recombinant version of the human blood-clotting protein thrombin (coagulation Factor Iia) Provides an effective and safe alternativ
Slide 17: Recothrom: topical hemostats market
Strategic fit Recothrom® Topical hemostats are biologic pharmaceuticals and medical devices that are used to control diffuse raw surface, oozing venous, bone, and suture needle-hole bleeding Topical hemostats are divided into four classes and each has around $200M in sales in the US market: Mechanic
Slide 18: Recothrom: range of presentations offers growth opportunities
Strategic fit Recothrom® A range of presentations offer growth opportunities Absorbable gelatin sponge Gelfoam® sponge Surgifoam® sponge Absorbable gelatin matrix Surgiflo® hemostatic matrix Absorbable gelatin powder Surgifoam® powder Gelfoam® powder Pump spray device Single spray device New develop
Slide 19: Ionsys: post-operative pain product
Strategic fit Ionsys® Post-operative pain product competing in the current ~$6B US/EU/Japan market Compact, needle-free, disposable patient controlled analgesia Late stage with US approval anticipated in Q1 2014 Peak revenue potential >$800M Strong leadership team with ALZA roots Potential to enable
Slide 20: Ionsys: clinical pharmacology vs IV fentanyl
Strategic fit Ionsys® Clinical pharmacology shows essentially bio-equivalence to IV fentanyl given every hour for 20 minutes iv Time (h) Serum fentanyl concentration (ng/mL) 1.5 1.0 0.5 0.0 0 4 8 12 16 20 24 28 32 36 40 44 48 IONSYS: 2 consecutive 40mcg doses/20 min Q1h IV fentanyl: 80mcg infusion/2
Slide 21: Ionsys: successfully completed phase III program
Strategic fit Ionsys® Successfully completed phase III clinical trial program Treatment success as measured by patient global assessment of pain control (%)Viscusi ER, et al. JAMA. 2004;291:1333-1341 Hartrick CT et al. Reg Anesth Pain Med. 2006;31(6):546-54 Minkowitz HS et al. Pain Medicine. 2006; 8
Slide 22: Ionsys: economic dominance over intravenous PCA
Strategic fit Ionsys® Published studies demonstrate economic dominance over intravenous PCA even in the HTA-oriented European arena Authors | presentation Country of study Main finding Annemans, EFIC 2006 Belgium €126-186 cost savings with IONSYS compared to IV PCA Standl, EFIC 2006 France, Germany,
Slide 23: Ionsys: original product problems and new system
Strategic fit Ionsys® Original product had problems with humidity in packaging This led to corrosion of electronic contacts EMA approved product with dessicant in package FDA approved product, not launched EMA recall in September 2008 due to corrosion Separated system created PK study established bi
Slide 24: Ionsys: rapid timeline to market
Strategic fit Ionsys® Rapid timeline to market anticipated – in all three regions US milestones PK bridging study Q2 2013 Practitioner/patient usability study Q2 2013 sNDA submission Q4 2013 CMC supplement - 4-month review Q4 2013 REMS supplement - 6-month review Q1 2014 US launch anticipated Q2 201
Slide 25: Ionsys: competitive review
Strategic fit Ionsys® Competitive review Company Product Description Marketed Cadence Ofirmev Stable formulation of intravenous acetaminophen Pacira Exparel Delivers post surgical pain control with reduced opioid requirement for up to 72 hours Cornerstone / EKR DepoDur Extended release epidural morp
Slide 26: Operating Leverage
OPERATING LEVERAGE page 26 [MOCO: ulding the Global Leader in Ate and intensive Care Meine | Investor Update December 17-18 2012
Slide 27: MDCO is a leading hospital company – adding human talent
Operating leverage MDCO is a leading hospital company – adding human talent with these deals Unique organization – built stepwise and specifically to address the unique challenges of acute and intensive care Collaboration with AstraZeneca - supporting their efforts to sell Brilinta in US hospitals.
Slide 28: De-risked Structures
DE-RISKED STRUCTURES page 28 MOCO: ulding the Global Leader in Ate and intensive Care Maine | Investor Update December 17-189 2012
Slide 29: Low development risk and structured financial arrangements
De-risked structures Low development risk and structured financial arrangements reduce early exposure Transaction structures suit our cash management and cash flow plans. Sufficient cash, attractive net income growth over time and adequate future cash flows from operations to take on these deals and
Slide 30: Both assets have favorable risk profiles
De-risked structures Both assets have favorable risk profiles Risk factors Recothrom® - BMS Ionsys® - Incline Therapeutics Development Marketed product Line extension research in process Phase III trials completed 15 years of prior development leverage No safety/efficacy trials required PK/PD profil
Slide 31: Effectively Timed Revenue, Cash-Flow and Earnings Development
VI EFFECTIVELY TIMED REVENUE, CASH-FLOW AND EARNINGS DEVELOPMENT
Slide 32: Sustainable growth anticipated
Effectively timed revenue, cash flow and earnings development Sustainable growth anticipated Accretion | dilution Recothrom® deal is expected to be accretive to earnings in 2013 Incline Therapeutics deal is expected to be modestly dilutive for 2013-15 Combined the deals are neutral to slightly negat
Slide 33: Principles of Integration - Moving Forward
VII PRINCIPLES OF INTEGRATION - MOVING FORWARD
Slide 34: Principles of integration: moving forward
Principles of integration Moving forward We expect to create the new merged leadership arrangements before closing Alan Levy, CEO of Incline Therapeutics will lead the Ionsys® innovation team reporting to MDCO Chief Executive Officer -- Incline team left to innovate BMS team will be merged and integ
Slide 35: Summary and Immediate Steps
VIII SUMMARY AND IMMEDIATE STEPS